Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders
| Autor: | John-Paul Taylor, Geor Bakker, Daniel Erskine, Alastair J. H. Brown, Pradeep J. Nathan, Tim Tasker |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Pharmacology medicine.medical_specialty business.industry Cognition Human brain medicine.disease 03 medical and health sciences 030104 developmental biology 0302 clinical medicine medicine.anatomical_structure Schizophrenia 030220 oncology & carcinogenesis Drug Discovery Muscarinic acetylcholine receptor Medicine Cholinergic Dementia business Psychiatry Receptor Acetylcholine medicine.drug |
| Zdroj: | Drug Discovery Today. 24:2307-2314 |
| ISSN: | 1359-6446 |
| Popis: | Cholinergic dysfunction is involved in a range of neurological and psychiatric disorders, including schizophrenia, dementia and Lewy body disease (LBD), leading to widespread use of cholinergic therapies. However, such drugs have focused on increasing the availability of acetylcholine (ACh) generally, with relatively little work done on the muscarinic system and specific muscarinic receptor subtypes. In this review, we provide an overview of the major cholinergic pathways and cholinergic muscarinic receptors in the human brain and evidence for their dysfunction in several neurological and psychiatric disorders. We discuss how the selectivity of cholinergic system dysfunction suggests that targeted cholinergic therapeutics to the muscarinic receptor subtypes will be vital in treating several disorders associated with cognitive dysfunction and behavioural and psychological symptoms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect